title: Relationship between metalloproteinase 2 and 9 concentrations and soluble CD154 expression in Iranian patients with multiple sclerosis.
abstract: Matrix metalloproteinases (MMPs) play a critical role in the blood-brain barrier permeability and in invasion of the leukocytes into the central nervous system during multiple sclerosis (MS). In this respect, in the present study, we have evaluated the possible role of MMP-9 and MMP-2 on the expression of soluble CD154 (sCD154) and membrane-bound isoform of the CD154 in Iranian MS patients. The expressions of the aforementioned protein-related genes were analyzed at the levels of messenger RNA and proteins by real-time reverse transcription polymerase chain reaction, enzyme-linked immunosorbent assay, and Western blotting. The results showed a high expression of CD154 isoforms, MMP-9 and MMP-2, in MS patients in contrast to controls (p < 0.001). We found an increase in sCD154 concentration (i.e., >3-fold) in patients with a higher MMPs/tissue inhibitor of metalloproteinase 1 (TIMP-1) ratio. Furthermore, secondary-progressive MS patients with exacerbate period showed higher positive correlation between increasing sCD154 concentration and overexpression of MMP-2 (p < 0.001). Our data demonstrate that following the exacerbation period, sCD154 concentration is increased in patients, which is mutually related to the MMPs/TIMP-1 ratio. This relationship may represent a new link between sCD154 concentration and the MMPs/TIMP-1 ratio with prognostic implications.
authors.affiliation: Department of Immunology, Zabol University of Medical Sciences, Zabol, Iran.
authors.forename: Javad
authors.initials: J
authors.lastname: Sanchooli
authors.affiliation: Department of Neurology, Zahedan University of Medical Sciences, Zahedan, Iran.
authors.forename: Nourollah
authors.initials: N
authors.lastname: Ramroodi
authors.affiliation: Department of Biology, Faculty of Science, Zabol University, Zabol, Iran; Pharmaceutical Science Research Center (PSRC), Tehran University of Medical Sciences (TUMS), Tehran, Iran. Electronic address: n.sanadgol@uoz.ac.ir.
authors.forename: Nima
authors.initials: N
authors.lastname: Sanadgol
authors.affiliation: Department of Biology, Faculty of Science, Zabol University, Zabol, Iran.
authors.forename: Vida
authors.initials: V
authors.lastname: Sarabandi
authors.affiliation: Department of Biology, Faculty of Science, Shahid Bahonar University, Kerman, Iran.
authors.forename: Hadi
authors.initials: H
authors.lastname: Ravan
authors.affiliation: Department of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Reza Saebi
authors.initials: RS
authors.lastname: Rad
mesh_terms: D000293:Adolescent; D000328:Adult; D015153:Blotting, Western; D023201:CD40 Ligand / Q000097:blood* / Q000235:genetics / Q000378:metabolism; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007492:Iran; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood*; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood* / Q000201:enzymology*; D020033:Protein Isoforms / Q000097:blood; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012995:Solubility; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism; D055815:Young Adult
chemical_list: D020033:Protein Isoforms; D012333:RNA, Messenger; C560822:TIMP1 protein, human; D019715:Tissue Inhibitor of Metalloproteinase-1; D023201:CD40 Ligand; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9
keywords: Matrix metalloproteinase-2 and matrix metalloproteinase-9; Multiple sclerosis; Soluble CD40 ligand; Tissue inhibitors of metalloproteinase 1
references.citation: Leuk Lymphoma. 2005 Aug;46(8):1105-13
references.pmid: 16085550
references.citation: J Neuroimmunol. 2005 May;162(1-2):28-42
references.pmid: 15833357
references.citation: J Immunol. 2005 Jul 1;175(1):124-30
references.pmid: 15972638
references.citation: Annu Rev Immunol. 2004;22:307-28
references.pmid: 15032580
references.citation: Int J Cancer. 2005 Jul 20;115(6):849-60
references.pmid: 15729716
references.citation: J Exp Med. 2006 Apr 17;203(4):1007-19
references.pmid: 16585265
references.citation: Hum Immunol. 2013 Jan;74(1):1-5
references.pmid: 23000501
references.citation: J Clin Invest. 1999 Jan;103(2):281-90
references.pmid: 9916140
references.citation: Arthritis Rheum. 2003 Mar;48(3):719-27
references.pmid: 12632425
references.citation: J Neurol Sci. 2007 Aug 15;259(1-2):79-84
references.pmid: 17382965
references.citation: Gut. 2004 Jul;53(7):1035-43
references.pmid: 15194658
references.citation: Scand J Immunol. 2000 Mar;51(3):312-20
references.pmid: 10736102
references.citation: Clin Biochem. 2010 Aug;43(12):968-72
references.pmid: 20451511
references.citation: Brain Behav Immun. 2004 Jan;18(1):7-12
references.pmid: 14651941
references.citation: FASEB J. 2005 Oct;19(12):1668-70
references.pmid: 16081501
references.citation: Trends Cardiovasc Med. 2010 Jul;20(5):153-64
references.pmid: 21742271
references.citation: J Neuroimmunol. 1999 May 3;96(2):158-66
references.pmid: 10337914
references.citation: J Clin Immunol. 2013 Jan;33(1):280-7
references.pmid: 22948742
references.citation: J Immunol. 2000 Sep 15;165(6):2962-9
references.pmid: 10975803
references.citation: J Leukoc Biol. 2000 Jan;67(1):2-17
references.pmid: 10647992
references.citation: Blood. 2008 Nov 1;112(9):3624-37
references.pmid: 18669876
references.citation: Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2499-504
references.pmid: 8637903
references.citation: Ann Neurol. 2005 Dec;58(6):840-6
references.pmid: 16283615
references.citation: Neurology. 1999 Oct 22;53(7):1397-401
references.pmid: 10534241
references.citation: Science. 1996 Sep 27;273(5283):1864-7
references.pmid: 8791592
references.citation: Am J Pathol. 2009 Mar;174(3):898-909
references.pmid: 19218336
references.citation: Clin Dev Immunol. 2012;2012:490148
references.pmid: 22110533
references.citation: Sci STKE. 2004 Jun 09;2004(237):pe25
references.pmid: 15199223
references.citation: Circulation. 2005 Apr 5;111(13):1690-6
references.pmid: 15795333
references.citation: Arthritis Rheum. 2002 Dec;46(12):3251-8
references.pmid: 12483729
references.citation: Neurol Res. 2013 Sep;35(7):693-700
references.pmid: 23561892
references.citation: Hematology. 2007 Aug;12(4):301-7
references.pmid: 17654056
references.citation: J Thromb Haemost. 2007 Apr;5(4):788-96
references.pmid: 17403203
references.citation: FASEB J. 2004 Nov;18(14):1682-91
references.pmid: 15522913
references.citation: J Immunol. 2007 Jul 15;179(2):753-63
references.pmid: 17617564
references.citation: Autoimmunity. 2004 Aug;37(5):411-8
references.pmid: 15621565
references.citation: Nat Rev Neurosci. 2001 Jul;2(7):502-11
references.pmid: 11433375
references.citation: J Neuroimmunol. 2002 Aug;129(1-2):58-65
references.pmid: 12161021
references.citation: Platelets. 2013;24(7):516-20
references.pmid: 22992131
references.citation: Circulation. 1999 Aug 10;100(6):614-20
references.pmid: 10441098
references.citation: J Neurosci. 2010 Jul 14;30(28):9454-64
references.pmid: 20631174
references.citation: PLoS One. 2012;7(3):e33925
references.pmid: 22470494
references.citation: J Neuroimmunol. 2003 Mar;136(1-2):46-53
references.pmid: 12620642
references.citation: Dis Markers. 2006;22(4):235-44
references.pmid: 17124345
references.citation: J Leukoc Biol. 2008 May;83(5):1069-78
references.pmid: 18198208
references.citation: J Exp Med. 1995 Jul 1;182(1):33-40
references.pmid: 7540655
references.citation: Brain Res Brain Res Rev. 2001 Oct;36(2-3):249-57
references.pmid: 11690622
references.citation: New Microbiol. 2011 Jul;34(3):263-74
references.pmid: 21811746
references.citation: Thromb Haemost. 2012 Jan;107(1):88-98
references.pmid: 22116092
references.citation: J Immunol. 1997 Nov 1;159(9):4620-7
references.pmid: 9379064